关于依达拉奉对急性脑梗死患者血清S100β蛋白和超敏C反应蛋白的影响.docVIP

关于依达拉奉对急性脑梗死患者血清S100β蛋白和超敏C反应蛋白的影响 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：关于依达拉奉对急性脑梗死患者血清S100β蛋白和超敏C反应蛋白的影响 1 1 对象与方法 2 2 结果 4 3 讨论 6 文2：奥扎格雷钠对急性脑梗死患者血清C反应蛋白与疗效的影响 7 1 资料与方法 8 2 结果 10 参考文摘引言： 10 原创性声明（模板） 11 文章致谢（模板） 12 正文 关于依达拉奉对急性脑梗死患者血清S100β蛋白和超敏C反应蛋白的影响 文1：关于依达拉奉对急性脑梗死患者血清S100β蛋白和超敏C反应蛋白的影响 【Abstract】 Objective To investigate the effects of edaravone on serum S100β protein and highseitivity Creactive protein (hsCRP) of acute cerebral A randomized doubleblind study was designed to value effects of edaravone on acute cerebral infarction， with routine therapy as placebocontrol group. One hundred and six patients were chosen from Mar 2006 to Jun 2008， which were pided into two groups: edaravone group (56 cases) and control group (50 cases).Serum levels of S100β protein， serum levels of hsCRP， improvement of neurological function and improvement of Barthel index were There was better clinical outcome in the two groups， P. There was a significant difference between two groups. In edaravone group， serum levels of S100β protein， serum levels of hsCRP， improvement of neurological function and improvement of Barthel index were elevated markedly compared with those in placebocontrol group(P).Conclusion Edaravone can significantly decrease the level of S100β protein and hsCRP， and improve the neurological function of acute cerebral infarction。 【Key words】 Cerebral infarction; Edaravone; S100β protein; hsCRP 本研究通过检测治疗前后ACI患者血清S100β、hsCRP水平的变化，探讨依达拉奉的脑保护作用及机制。 1 对象与方法 对象 系200603～200810我院收治的ACI患者106例，年龄48～80岁；发病6～24h内，个别进展者可延长到24～72h；符合全国第4届脑血管病学术会议修订的诊断标准，并经头部CT或MRI检查证实；排除近期有感染、外伤或严重的心、肝、肾功能损害；无严重精神疾病或其他脑部器质性病变；无过敏素质。随机分为2组：（1）依达拉奉组56例，男36例，女20例；年龄49～80岁，中位年龄67岁；发病6～12h 20例，＞12～24h 22例，＞24～48h 8例，＞48～72h 6例。按1995年全国第四届脑血管病学术会议通过的脑卒中患者临床神经功能缺损程度评分标准，按病情轻重分为轻型（0～15分）16例，中型（16～30分）22例，重型（31～45分）18例。按梗死面积大小分为腔隙性梗死组（面积≤）15例， 小面积梗死组（ cm2＜面积≤5cm2）23例， 大面积梗死组（面积＞5cm2）18例。（2）常规治疗组50例，男32例，女18例；年龄48～78岁，中位年龄65岁；发病6～12